DRREDDY · NSE
Dr. Reddy's Laboratories Limited
₹1,185
+0.85% (+₹10)
Prev. close
₹1,175
Volume
30,02,566
Delivery %
58.1%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
4 analyst stances · last 90 days · one per analyst
Trackable
3 · 3 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
1 · 0 bull / 0 neutral / 1 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Dr Reddy’s Labs, recommending a buy at ₹1165 with a target of ₹1290 and a stop loss at ₹1100. The stock is at…” | Sumeet BagadiaChoice Equity Broking | Dr Reddy's Laboratories | PENDING | |
| “Bullish on Dr. Reddy's Laboratories for the short term, with a target price of ₹1,480 and a stop loss at ₹1,300. The sto…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Dr. Reddy's Laboratories | MISS | |
| “Nomura maintains a 'buy' rating on Dr. Reddy's Laboratories with a price target of ₹1,740, implying a 29% upside. The br…” | Nomura AnalysisNomura Global Markets Research | Dr. Reddy's Laboratories | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Motilal Oswal lowered Dr Reddy's Laboratories' FY27 EPS estimate by 19% to ₹37.2 from ₹45.9, anticipating a 37% decline …” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Dr Reddy's Laboratories | PENDING |
Fundamentals
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Erez Israeli M.B.A.
Headquarters
Hyderabad
Employees
27,527
Website
drreddys.comExchange
View on NSE ↗Key stats
Market cap
₹97,876.16 Cr
P/E ratio (TTM)
29.6
Dividend yield
0.70%
EPS (TTM)
₹39.67
Beta (1Y · daily vs NIFTY 50)
0.50
Beta (5Y · monthly vs NIFTY 50)
0.46
Shares float
60.00 Cr
EPS · quarter ended Jun 2026
₹5.32
Upcoming earnings
22 Oct 2026
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹19,047.50 Cr | ₹21,545.20 Cr | ₹24,669.70 Cr | ₹28,011.10 Cr | ₹32,643.90 Cr | ₹33,700.20 Cr | |
| EBITDA | ₹4,161.30 Cr | ₹4,252.10 Cr | ₹7,443.10 Cr | ₹8,827.40 Cr | ₹9,644.40 Cr | ₹7,916.00 Cr |
| ₹1,952.00 Cr | ₹2,182.00 Cr | ₹4,506.70 Cr | ₹5,577.90 Cr | ₹5,655.10 Cr | ₹4,285.00 Cr | |
| Diluted EPS | ₹23.47 | ₹26.24 | ₹54.18 | ₹66.92 | ₹67.79 | ₹51.42 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹26,616.80 Cr | ₹29,746.90 Cr | ₹32,285.10 Cr | ₹38,780.00 Cr | ₹48,023.00 Cr | ₹56,577.00 Cr | |
| ₹3,030.80 Cr | ₹3,004.50 Cr | ₹608.20 Cr | ₹2,002.00 Cr | ₹4,676.60 Cr | ₹7,734.10 Cr | |
| Stockholders' equity | ₹17,641.70 Cr | ₹19,212.40 Cr | ₹23,286.10 Cr | ₹28,254.00 Cr | ₹33,549.00 Cr | ₹37,892.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,570.30 Cr | ₹2,810.80 Cr | ₹5,888.00 Cr | ₹4,543.00 Cr | ₹4,643.00 Cr | ₹5,674.00 Cr | |
| Investing cash flow | ₹-2,266.00 Cr | ₹-2,638.70 Cr | ₹-4,137.10 Cr | ₹-4,028.30 Cr | ₹-5,807.70 Cr | ₹-6,549.30 Cr |
| ₹-29.80 Cr | ₹-242.20 Cr | ₹-2,686.10 Cr | ₹-376.30 Cr | ₹1,891.10 Cr | ₹829.00 Cr | |
| Capital expenditure | ₹-1,256.10 Cr | ₹-1,904.90 Cr | ₹-1,887.00 Cr | ₹-2,744.00 Cr | ₹-3,440.00 Cr | ₹-3,840.00 Cr |
| End cash position | ₹1,482.90 Cr | ₹1,485.20 Cr | ₹577.90 Cr | ₹710.70 Cr | ₹1,459.30 Cr | ₹1,536.80 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.72% | 26.72% | 26.71% | 26.71% | 26.70% | 26.70% | 26.69% | 26.66% | 26.65% | 26.65% | 26.65% | 26.64% | 26.64% | 26.64% | 26.64% | 26.64% | 26.63% | 26.64% |
| Public | 72.99% | 73.00% | 73.01% | 73.02% | 73.05% | 73.08% | 73.10% | 73.16% | 73.17% | 73.17% | 73.18% | 73.20% | 73.07% | 73.10% | 73.11% | 73.12% | 73.13% | 73.16% |
| Employee trusts | 0.29% | 0.28% | 0.28% | 0.27% | 0.25% | 0.22% | 0.21% | 0.18% | 0.18% | 0.17% | 0.17% | 0.16% | 0.29% | 0.26% | 0.25% | 0.25% | 0.24% | 0.20% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
27 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.